Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Verastem
(NASDAQ:VSTM)
Intraday
$9.105
-0.205
[-2.20%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$9.105
-0.205
[-2.20%]
Last update: 11:33AM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Verastem Stock (NASDAQ:VSTM)
Verastem Stock (NASDAQ: VSTM)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, April 09, 2024
Verastem Oncology Partner GenFleet Therapeutics Unveils Latest Research Findings Of GFH375 At AACR Annual Meeting
Benzinga Newsdesk
-
Apr 9, 2024, 7:16AM
Tuesday, March 19, 2024
HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $17.5 Price Target
Benzinga Newsdesk
-
Mar 19, 2024, 6:38AM
Friday, March 15, 2024
RBC Capital Reiterates Outperform on Verastem, Maintains $32 Price Target
Benzinga Newsdesk
-
Mar 15, 2024, 12:46PM
Thursday, March 14, 2024
Recap: Verastem Q4 Earnings
Benzinga Insights
-
Mar 14, 2024, 5:55PM
Verastem Q4 2023 Adj EPS $(1.10) Misses $(0.62) Estimate
Benzinga Newsdesk
-
Mar 14, 2024, 4:17PM
Monday, March 11, 2024
Verastem Oncology Announces Multiple Oral Presentations At Society Of Gynecologic Oncology 2024 Annual Meeting On Women's Cancer
Benzinga Newsdesk
-
Mar 11, 2024, 7:48AM
Tuesday, March 05, 2024
Verastem Oncology Secures FDA Orphan Drug Designation For Avutometinib Alone Or In Combination With Defactinib In Recurrent Low-Grade Serous Ovarian Cancer
Benzinga Newsdesk
-
Mar 5, 2024, 5:29PM
Verastem Oncology Announces Preclinical Presentations For New Oral G12D Inhibitor And For Avutometinib And Defactinib Combination As A Backbone Of Therapy For RAS/MAPK Driven Cancers At AACR Annual Meeting 2024
Benzinga Newsdesk
-
Mar 5, 2024, 4:37PM
Monday, February 12, 2024
Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Avi Kapoor
-
Feb 12, 2024, 1:07PM
Monday, January 29, 2024
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
Benzinga Newsdesk
-
Jan 29, 2024, 7:04AM
Thursday, January 18, 2024
Verastem Oncology Granted Fast Track Designation For Combination Of Avutometinib And Sotorasib For The Treatment Of KRAS G12C-Mutant Non-Small Cell Lung Cancer
Benzinga Newsdesk
-
Jan 18, 2024, 4:00PM
Monday, December 18, 2023
Verastem Oncology Announced A Potential KRAS G12D Oral Inhibitor As The Lead Program Of Its Discovery And Development Collaboration With Genfleet Therapeutics; Investigational New Drug Submission Planned for GFH375/VS-7375 in H1 2024
Benzinga Newsdesk
-
Dec 18, 2023, 7:50AM
Wednesday, December 13, 2023
Verastem Oncology Has Initiated Its International Confirmatory Phase 3 RAMP 301 Trial Of Avutometinib And Defactinib Combo Versus Standard Chemotherapy Or Hormonal Therapy For Recurrent Low-grade Serous Ovarian Cancer
Benzinga Newsdesk
-
Dec 13, 2023, 7:02AM
Tuesday, November 21, 2023
BTIG Assumes Verastem at Buy, Announces Price Target of $27
Benzinga Newsdesk
-
Nov 21, 2023, 8:36AM
Wednesday, November 15, 2023
Where Verastem Stands With Analysts
Benzinga Insights
-
Nov 15, 2023, 12:01PM
Truist Securities Maintains Buy on Verastem, Lowers Price Target to $34
Benzinga Newsdesk
-
Nov 15, 2023, 11:56AM
Wednesday, November 08, 2023
Verastem Q3 EPS $(0.71) Beats $(0.84) Estimate
Benzinga Newsdesk
-
Nov 8, 2023, 5:28PM
Friday, October 27, 2023
Verastem Chief Financial Officer Awarded $162K Worth of Stock Options
Benzinga Insights
-
Oct 27, 2023, 11:00AM
Thursday, October 26, 2023
Verastem Oncology Strengthens Executive Leadership Team With Key Appointments; Dan Calkins Promoted To Chief Financial Officer From Vice President Of Finance
Benzinga Newsdesk
-
Oct 26, 2023, 4:47PM
Monday, October 16, 2023
Reported Earlier, Verastem Oncology Announced Initial Results Of RAMP 203 Trial Of Avutometinib And LUMAKRAS™ In KRAS G12C-Mutant Non-Small Cell Lung Cancer
Benzinga Newsdesk
-
Oct 16, 2023, 2:32AM
Friday, September 29, 2023
B. Riley Securities Reiterates Buy on Verastem, Maintains $21 Price Target
Benzinga Newsdesk
-
Sep 29, 2023, 10:01AM
Thursday, September 28, 2023
Verastem Presents Avutometinib And Defactinib Combination Program Updates At The 5th Annual RAS-Targeted Drug Development Summit
Benzinga Newsdesk
-
Sep 28, 2023, 2:16PM
Wednesday, September 27, 2023
Analyst Ratings for Verastem
Benzinga Insights
-
Sep 27, 2023, 5:00PM
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
Benzinga Insights
-
Sep 27, 2023, 11:00AM
B. Riley Securities Initiates Coverage On Verastem with Buy Rating, Announces Price Target of $21
Benzinga Newsdesk
-
Sep 27, 2023, 5:08AM
Tuesday, August 29, 2023
Mizuho Reiterates Buy on Verastem, Maintains $36 Price Target
Benzinga Newsdesk
-
Aug 29, 2023, 9:40AM
Monday, August 28, 2023
Verastem Oncology Partners With Genfleet Therapeutics For Three Oncology Discovery Programs For $11.5M To Genfleet For The First Program, With Potential Deal Size Across All Three Programs Up To $625.5M Excluding Royalties If Verastem Exercises Its Option
Benzinga Newsdesk
-
Aug 28, 2023, 7:05AM
Wednesday, August 09, 2023
RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $32
Benzinga Newsdesk
-
Aug 9, 2023, 11:48AM
Tuesday, August 08, 2023
Verastem Q2 EPS $(1.06) Beats $(1.07) Estimate
Benzinga Newsdesk
-
Aug 8, 2023, 5:21PM
Tuesday, July 11, 2023
Truist Securities Maintains Buy Rating for Verastem: Here's What You Need To Know
Benzinga Insights
-
Jul 11, 2023, 1:00PM
Truist Securities Maintains Buy on Verastem, Lowers Price Target to $39
Benzinga Newsdesk
-
Jul 11, 2023, 8:11AM
Verastem Oncology Announced That Dan Paterson, President & COO, Has Been Promoted To President & CCEO. Brian Stuglik Will Retire From The CEO Role And Remain A Board Member, Effective August 1
Benzinga Newsdesk
-
Jul 11, 2023, 7:07AM
Thursday, July 06, 2023
Cantor Fitzgerald Reiterates Overweight on Verastem, Maintains $34 Price Target
Benzinga Newsdesk
-
Jul 6, 2023, 8:01AM
Wednesday, July 05, 2023
Verastem Oncology Announces Design For Confirmatory Trial Of Avutometinib And Defactinib In Recurrent Low-Grade Serous Ovarian Cancer; As Of March 31, 2023, Verastem Oncology Had Cash And Short-Term Investments Of $111.2M
Happy Mohamed
-
Jul 5, 2023, 4:11PM
Monday, July 03, 2023
RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $34
Benzinga Newsdesk
-
Jul 3, 2023, 9:38AM
Tuesday, June 27, 2023
Truist Securities Reiterates Buy on Verastem, Maintains $60 Price Target
Benzinga Newsdesk
-
Jun 27, 2023, 8:53AM
Friday, June 23, 2023
Truist Securities Reiterates Buy on Verastem, Maintains $60 Price Target
Benzinga Newsdesk
-
Jun 23, 2023, 12:32PM
Friday, June 16, 2023
Why Clene Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Jun 16, 2023, 8:10AM
Verastem Oncology shares are trading lower after the company priced its public offering of 7.2M shares at $9.75/share and pre funded warrants to purchase up to 1.5M shares at $9.749/warrant.
Benzinga Newsdesk
-
Jun 16, 2023, 5:47AM
Verastem Oncology Priced Its Underwritten Public Offering Of 7.18M Shares At $9.75/Share And Pre-funded Warrants To Purchase Up To 1.54M Shares At $9.749 Per Pre-funded Warrant, With Gross Proceeds Of Approximately $85M
Benzinga Newsdesk
-
Jun 16, 2023, 5:44AM
Thursday, June 15, 2023
Verastem Oncology Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants; No Terms Disclosed
Benzinga Newsdesk
-
Jun 15, 2023, 4:00PM
Crude Oil Rises Sharply; Jabil Posts Upbeat Q3 Results
Lisa Levin
-
Jun 15, 2023, 2:52PM
Verastem's Ovarian Cancer Drug Showing Promise, Analyst Upgrades Stock
Vandana Singh
-
Jun 15, 2023, 2:03PM
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Jun 15, 2023, 1:31PM
Verastem shares are trading higher after Mizuho upgraded the stock to Buy from Neutral and raised the price target from $24 to $36
Benzinga Newsdesk
-
Jun 15, 2023, 1:03PM
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023
Benzinga Insights
-
Jun 15, 2023, 11:01AM
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
-
Jun 15, 2023, 9:07AM
Verastem To Rally Around 287%? Here Are 10 Other Analyst Forecasts For Thursday
Lisa Levin
-
Jun 15, 2023, 8:10AM
Mizuho Upgrades Verastem to Buy, Raises Price Target to $36
Benzinga Newsdesk
-
Jun 15, 2023, 5:15AM
Wednesday, June 14, 2023
Pancreatic Cancer Action Network Urges Advocates From All 50 States To Call On Congress To Increase Federal Funding For Pancreatic Cancer Research
Benzinga Newsdesk
-
Jun 14, 2023, 9:13AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch